Med Polonia Sp. z o.o. — Clinical Trial Site

109 Registered trials

35 Currently recruiting

Organisation

Med Polonia Sp. z o.o.

Location

Poznan, Poland

Identifier

ORG-100041354

Address

Ul. Obornicka 262, 60-693, Poland

Departments

-
1906
5703 : MED-POLONIA Sp.z o.o.
8503
Badania Kliniczne
Clinical Trials
Clinical Trials Department
Department and Clinic of Neurology
Department of Cardio-thoracic Surgery
Dermatology
Dział badań klinicznych
Dział badań klinicznych
Hospital and Outpatient Clinic
Katedra i Klinika Onkologii
Limited liability company
Med - Polonia Sp. z o.o.
Med – Polonia Sp. z o.o.
Med Polonia
Med Polonia Sp. z o.o.
Med-Polonia
Med-Polonia Sp. z o.o.
Med-Polonia SP.z o.o.
Med-Polonia Spółka z Ograniczoną Odpowiedzialnością
N/A
n/d
NA
NA/ND
Not Applicable
not applicable/nie dotyczy
NZOZ Med-Polonia Sp. z o.o.
Oncology
Onkologia
Onkologii
Przychodnia MED-POLONIA
Przychodnia Med-Polonia, Poradnia Onkologiczna

Clinical trials at this site (109)

Search interface

A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended

2022-501234-37-00 Solid Tumours 7 2024-05-07
Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended

2022-502916-35-01 Advanced Non-Small Cell Lung Cancer 4 2024-03-27
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small… Ended

2023-506008-20-00 Extensive-stage small cell lung carcinoma (ES-SCLC) 3 2024-01-11
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Ended

2022-503114-23-00 Breast Cancer 3 2023-12-19
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 7 2023-11-27
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L… Ended

2024-515047-31-00 Patients with Limited-Stage Small Cell Lung Cancer (LS- 5 2023-08-28
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut… Ended

2024-511548-19-00 Pancreatic Ductal Adenocarcinoma 1 2022-12-13
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Metastatic or Locally Advanced Epidermal Growth Factor 5 2022-09-01
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended

2023-506518-33-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2021-11-10
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung… Ended

2024-513770-22-00 Malignant Solid Tumors - Non Small Cell Lung Cancer 4 2021-09-22
DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Ended

2023-509865-19-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2021-04-30
Inebilizumab efficacy and safety in adults with myasthenia gravis Ended

2023-510006-40-00 Myasthenia Gravis which is either due to acetylcholine 5 2021-03-22
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC… Ended

2023-507475-21-00 Lung Cancer, Non-Small Cell 10 2021-01-18
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502609-14-00 Relapsing multiple sclerosis (RMS) 5 2020-12-09